通过AMPK上调调节,SGLT2i通过减少ferroptosis持续预防心脏缩
Bing-Bing Zhao1,2, Jiao Wang1, Lu-Lu Zhang1
1Department of Cardiology, The First Hospital of Shanxi Medical University, No.85, Xinjian Road, Taiyuan City, 030001, Shanxi Province, China.
Molecular and cellular biochemistry
|April 26, 2025
概括
-葡萄糖共传输体2抑制剂 (SGLT2i) 通过激活腺单酸盐激活蛋白激酶 (AMPK) 来保护心脏缩,从而抵制铁灭亡. 这表明SGLT2i是早期心脏缩检测和治疗的潜在治疗方法.
科学领域:
- 心血管研究研究心血管研究
- 分子心脏病学分子心脏病学
- 代谢性疾病 代谢性疾病
背景情况:
- 心脏缩是心力衰竭的重要危险因素和预后指标.
- 早期干预对于管理心脏缩和改善患者结果至关重要.
- 腺单酸激活蛋白激酶 (AMPK) 在心脏缩中的持续作用和精确机制尚不清楚.
研究的目的:
- 研究AMPK激活在心脏缩中的持续作用.
- 阐明AMPK影响心脏缩和铁亡的潜在机制.
- 评估SGLT2抑制剂 (SGLT2i) 在预防心脏缩方面的治疗潜力.
主要方法:
- 建立了心脏缩的体内 (老鼠腹腔大动脉缩) 和体内 (用异二醇治疗的H9C2细胞) 模型.
- 在12周内服用SGLT2抑制剂 (SGLT2i) 激活AMPK并评估心脏功能.
- 分析了心脏组织的形态变化,纤维化和铁化;检查了细胞氧化应激和谷氨过氧化酶4 (GPX4) 水平.
主要成果:
- 心脏缩诱导了显著的组织病理变化,包括心肌细胞扩大,纤维化和铁化,随着时间的推移而持续.
- SGLT2i治疗有效地预防了这些过度变化和铁亡.
- AMPK对抗性加剧了氧化应激和铁亡,而SGLT2i的保护作用被部分取消,揭示了AMPK和铁亡之间的调节联系.
结论:
- 通过激活AMPK,SGLT2i可以抵消铁亡,从而提供对心脏缩的持续保护.
- 这项研究揭示了AMPK和铁死在心脏缩中的新型调节作用.
- SGLT2i显示出作为心脏缩治疗剂的潜力,血AMPK水平降低可能作为早期诊断标志物.
更多相关视频
06:51Isolation and Culture of Adult Mouse Cardiomyocytes for Cell Signaling and in vitro Cardiac Hypertrophy
Published on: May 21, 2014
47.5K
08:00Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
6.1K
相关概念视频
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
01:09GPCRs Regulate Adenylyl Cylase Activity
5.0K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.0K
01:25cAMP-dependent Protein Kinase Pathways
6.0K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.0K